Craig Goodwin

Craig Goodwin has a diverse work experience in the field of biology and research. Craig started their career as a Summer Research Intern at Furman University in 2007, followed by a Research Experience for Undergraduates at the University of Alabama in 2008. In 2009, they joined Vanderbilt University as a Graduate Student, where they focused on discovering inhibitors for KRAS, MCL-1, and PAK-1. At Vanderbilt, they conducted fragment screens, developed screening assays, and validated target engagement in cells.

From 2016 to 2021, Craig worked as a Postdoctoral Fellow at the University of North Carolina at Chapel Hill. During this time, they discovered novel combinations to treat KRAS-mutant pancreatic cancer, using CRISPR dropout screening and RPPA techniques. Craig also uncovered a MYC-centric paradigm for combinatorial targeting of KRAS-mutant cancers.

In 2022, Craig joined Reactive Biosciences as a Scientist II. In this role, they serve as the Biology lead for a small-molecule oncology discovery project, managing the execution of progression funnel biology assays, designing MOA studies, and contributing to pitch presentations. Craig also has additional responsibilities in platform expansion, Spotfire database configuration, data upload, and competitive intelligence.

Craig Goodwin has a strong educational background, having pursued higher education at both Vanderbilt University and Erskine College. Craig completed their Bachelor of Science degree in Biochemistry at Erskine College from 2005 to 2009. Later, they went on to pursue a Doctor of Philosophy (PhD) in Pharmacology from Vanderbilt University, which they obtained from 2009 to 2015.